Edition:
United States

Kamada Ltd (KMDA.TA)

KMDA.TA on Tel Aviv Stock Exchange

2,570.00ILa
23 Apr 2017
Change (% chg)

-10.00 (-0.39%)
Prev Close
2,580.00
Open
2,559.00
Day's High
2,600.00
Day's Low
2,559.00
Volume
5,319
Avg. Vol
103,745
52-wk High
2,710.00
52-wk Low
1,401.00

Latest Key Developments (Source: Significant Developments)

Kamada announces collaboration with Massachusetts General Hospital
Tuesday, 21 Feb 2017 06:30am EST 

Kamada Ltd : Kamada Ltd - announced a collaboration with Massachusetts General Hospital . Kamada Ltd - a collaboration to conduct a proof of concept study evaluating potential benefit of co's liquid Alpha-1 antitrypsin on liver preservation .Kamada - purpose of study is to evaluate effect of Kamada's liquid AAT on graft quality and viability, assess graft for markers of IRI caused to liver.  Full Article

Kamada Q4 loss per share $0.05
Monday, 6 Feb 2017 06:30am EST 

Kamada Ltd : Kamada Ltd - reaffirms revenue guidance of $100 million for 2017 . Kamada reports financial results for the fourth quarter and full-year 2016 . Q4 loss per share $0.05 . Q4 revenue fell 5.5 percent to $24.3 million . Sees FY 2017 revenue $100 million .Kamada Ltd - as of December 31, 2016, Kamada had cash, cash equivalents and short-term investments of $28.6 million.  Full Article

Kamada announces positive scientific advice response from the European Medicines Agency
Monday, 23 Jan 2017 06:30am EST 

Kamada Ltd : Kamada announces positive scientific advice response from the European Medicines Agency focused on Alpha-1 antitrypsin IV for treatment of acute graft-versus-host disease . In process of reviewing guidance received and, following discussions with company's European Scientific Advisory Board . Kamada Ltd- Intends to submit a clinical trial authorization (CTA) application to EMA in 2017 in order to conduct phase 2/3 study .Kamada Ltd- Intends to conduct European Study in parallel with U.S. Study.  Full Article

Kamada announces collaboration agreement with Yissum for Development of a Recombinant Human Alpha 1 Antitrypsin
Tuesday, 15 Nov 2016 07:00am EST 

Kamada Ltd :Press release - Kamada announces collaboration agreement with Yissum for development of a recombinant human Alpha 1 Antitrypsin.  Full Article

Kedrion Biopharma, Kamada- FDA accepts rabies immunoglobulin review
Monday, 7 Nov 2016 07:00am EST 

Kamada Ltd : Kamada ltd- pdufa goal date of august 29, 2017 .Kedrion biopharma and kamada announce fda acceptance of bla submission for human rabies immunoglobulin as a post-exposure treatment.  Full Article

Kamada and Kedrion seek FDA approval of human rabies immunoglobulin
Thursday, 1 Sep 2016 06:29am EDT 

Kamada Ltd : Kamada and Kedrion seek FDA approval of human rabies immunoglobulin as a post-exposure treatment .Companies planning for decision from FDA in mid-2017.  Full Article

Kamada meets primary endpoint of U.S. Phase 2 study of inhaled Alpha-1 Antitrypsin
Tuesday, 30 Aug 2016 06:30am EDT 

Kamada Ltd : Kamada meets primary endpoint of U.S. Phase 2 study of inhaled Alpha-1 Antitrypsin for the treatment of Alpha-1 Antitrypsin deficiency . There were no differences seen in safety parameters between placebo and treatment groups .To utilize results to design U.S. study and support responses to EMA regarding Co's marketing authorization application for inhaled AAT.  Full Article

Kamada reports Q2 adjusted loss per share $0.11
Tuesday, 2 Aug 2016 06:30am EDT 

Kamada Ltd : Kamada reports financial results for the second quarter and first six months of 2016 . Q2 loss per share $0.04 . Sees FY 2017 sales $100 million . Q2 revenue $19.1 million versus $19.2 million .Sees FY 2016 revenue $75 million to $80 million.  Full Article

Shire and Kamada announce FDA approval of an expanded label for GLASSIA
Wednesday, 15 Jun 2016 07:00am EDT 

Shire PLC : Shire and Kamada announce FDA approval of expanded label for self-infusion of GLASSIA for the treatment of emphysema due to severe AAT deficiency . Serious adverse reaction observed during clinical trials was exacerbation of chronic obstructive pulmonary disease .Infusion of GLASSIA for the treatment of emphysema due to severe AAT deficiency.  Full Article

Kamada Ltd reports positive interim data in phase 1/2
Wednesday, 6 Jan 2016 07:00am EST 

Kamada Ltd:Reports further positive interim data from phase 1/2 study of its alpha-1 antitrypsin to treat graft versus host disease.Says interim results showed that plasma aat levels increased in both cohorts and remained stable for the duration of treatment.Says treatment responses were evaluated as "peak" response and at day 28.Eight of the twelve subjects showed an overall response to treatment, four of which were complete responses and four were partial responses.  Full Article

More From Around the Web

BRIEF-Kamada announces collaboration with Massachusetts General Hospital

* Kamada Ltd - announced a collaboration with Massachusetts General Hospital